Quantification of tumor tissue populations by multispectral analysis
Quantification of tumor tissue populations by multispectral analysis
复制标题
DOI：
10.1002/mrm.10731
复制
发表时间：
2004-03-01
影响因子：
3.3
通讯作者：
Van Bruggen, N
中科院分区：
文献类型：
--
作者：
Carano, RAD;Ross, AL;Van Bruggen, N
肿瘤异质性使通过MRI定量治疗反应复杂化。为了解决这个问题，已经开发了一种新的方法，将MR扩散成像与多光谱（MS）分析相结合，以量化肿瘤组织群体。采用表观扩散系数（ADC）、T-2和质子密度（M-o）的K均值（KM）聚类来估计人结肠直肠肿瘤异种移植小鼠模型中活肿瘤组织、坏死和相邻皮下脂肪组织的体积。在第二组实验中，观察了MS组织类别响应于治疗性干预Apo 2L/TRAIL和CPT-11的时间演变。多个参数在识别各种组织中发挥互补作用。ADC是确定坏死区域的主要参数，而T-2确定了两个坏死亚群，M-o有助于从皮下脂肪组织中区分活肿瘤。MS存活肿瘤估计值（平均体积= 275 +/- 147 mm（3））与组织学估计值（1117 +/- 51 mm）高度相关（r = 0.81，P < 0.01）。在治疗研究中，Apo 2L/TRAIL+CPT-11组的MS存活肿瘤体积（第10天）为77 +/- 67 mm（3），相对于对照组（292 +/- 127 mm（3），p < 0.01）显著降低。该方法显示出作为体内检测早期治疗反应的手段的前景。(C)2004 Wiley-Liss，Inc.
Tumor heterogeneity complicates the quantification of a therapeutic response by MRI. To address this issue, a novel approach has been developed that combines MR diffusion imaging with multispectral (MS) analysis to quantify tumor tissue populations. K-means (KM) clustering of the apparent diffusion coefficient (ADC), T-2, and proton density (M-o) was employed to estimate the volumes of viable tumor tissue, necrosis, and neighboring subcutaneous adipose tissue in a human colorectal tumor xenograft mouse model. In a second set of experiments, the temporal evolution of the MS tissue classes in response to therapeutic intervention Apo2L/TRAIL and CPT-11 was observed. The multiple parameters played complementary roles in identifying the various tissues. The ADC was the dominant parameter for identifying regions of necrosis, whereas T-2 identified two necrotic subpopulations, and M-o contributed to the differentiation of viable tumor from subcutaneous adipose tissue. MS viable tumor estimates (mean volume = 275 +/- 147 mm(3)) were highly correlated (r = 0.81, P < 0.01) with histological estimates (1117 +/- 51 mm). In the treatment study, MS viable tumor volume (at day 10) was 77 +/- 67 mm(3) for the Apo2L/TRAIL+CPT-11 group, and was significantly reduced relative to the control group (292 +/- 127 mm(3), p < 0.01). This method shows promise as a means of detecting an early therapeutic response in vivo. (C) 2004 Wiley-Liss, Inc.